Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. - Wikidata - wikimedia - TriplyDB

Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.

Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.

http://www.wikidata.org/entity/Q37361549

about

Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression Lapatinib for the treatment of breast cancer in the People's Republic of China.Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer.Emerging kinase inhibitors of the treatment of gastric cancer.Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.Impact of phosphoproteomics in the translation of kinase-targeted therapies.MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.Early phosphoproteomic changes for adverse outcome pathway development in the fathead minnow (Pimephales promelas) brain.

P2860

Q26799900-821D8100-3BE7-4747-9DCA-87F23FC436B6 Q33648150-66710498-F3E7-4E55-8347-85CB03D06B01 Q33829405-8E2926B6-50CE-4CAC-94D8-1B26B2425FF6 Q34016491-99257883-EB69-4167-954D-9754B1D65D0D Q35930811-F0E21C8D-A9B5-499B-B960-8069B2DBC30E Q36750684-EDB20D32-A98E-47DC-98E7-C5B424FCE56A Q37609793-2E3F59C9-64AF-40CF-846E-B59569A7C245 Q38263575-D49AB07D-4007-4A1D-99FB-82FE9D4D481F Q38434942-D5FC4A72-9A1B-4ECB-8958-CE8DF433898D Q38506084-47217442-5D2C-4DD1-B6F8-80DF8EFBE31B Q38607782-5111F501-BF6F-48D9-B89C-807745663FB7 Q38675350-B6323085-AC1F-4FAE-97DB-385F56F17EAB Q38812867-39D34B34-0BF8-4F99-B217-5E22EFC2DAFD Q38845681-9769CFC5-7968-4888-9FDF-9E1074C0312B Q38989188-45E307E1-F8BD-476C-BAAD-AD7B75F6DC40 Q50417171-5FD07C2A-56AB-405C-8611-4E6709218387 Q55687881-7CB5247C-CFEB-4096-A605-3AFA02EAE57F

P2860

Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.

http://www.wikidata.org/entity/Q37361549

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Phosphoproteomic analysis iden ...... ib-resistant cancer cell line.

@en

Phosphoproteomic analysis iden ...... ib-resistant cancer cell line.

@nl

type

label

Phosphoproteomic analysis iden ...... ib-resistant cancer cell line.

@en

Phosphoproteomic analysis iden ...... ib-resistant cancer cell line.

@nl

prefLabel

Phosphoproteomic analysis iden ...... ib-resistant cancer cell line.

@en

Phosphoproteomic analysis iden ...... ib-resistant cancer cell line.

@nl

P1433

Q37361549-867ADE95-F61E-472D-8371-E3008BA07C50

P1476

Q37361549-27871377-603E-45A3-BB02-54583524B674

P2093

Q37361549-0569CE5A-0E8A-4507-9940-BAE4B9D80855

Q37361549-550C6D03-E101-44A2-8CE8-C393DD1A6F18

Q37361549-5531259A-D021-48C7-9D91-62457FDB079C

Q37361549-65DDAFBE-EC46-43EB-8912-87739845E63C

Q37361549-B5123D53-D091-440B-9FB3-A1AD1739ED96

Q37361549-C12AB5C8-4C02-433A-9ED9-09FA1F40C0B2

Q37361549-D6E0062A-BBB1-4120-B1A3-FEF4D1DEC289

P2860

Q37361549-099BA569-C137-4383-9979-A7C324B5E0E5

Q37361549-09FF09F5-0087-4802-8548-C25CA05C6731

Q37361549-0B269579-AE0D-43CA-A6FD-5F1AFC2E921D

Q37361549-195BC929-657E-4701-8354-0BE735DF76C4

Q37361549-1B5C1DC0-9A2C-4B96-A73C-7EAB1501B234

Q37361549-243AEB22-1EDD-4089-BD88-B7F2190DCCA4

Q37361549-27E05371-BCB4-453D-83EE-3E8A8614BFC5

Q37361549-3CE8A6C3-E083-41E0-A31A-16857D672FFC

Q37361549-4383DF95-FEF3-4174-A566-DF416CF4ABE0

Q37361549-4512648B-071A-46A3-87CC-6FA8A3580897

P2888

Q37361549-759DC9E1-B149-4B7A-8E0C-6426E89DBF5B

P304

Q37361549-10285CA9-BDD4-4F55-9CFA-007BD45BC6F6

P31

Q37361549-05D9EB72-2307-4889-ACFE-B8B8ABC2CD8F

P356

Q37361549-0F11E69C-420A-4CFA-872C-5DA06FFC99B8

P478

Q37361549-415FBB7E-4FE4-44A8-9632-23F6651F92CB

P577

Q37361549-2CF25440-5DAC-4B45-956B-57731DB207D5

P5875

Q37361549-CB93D21F-A4BF-4ADA-BA0B-EAE07AC3BD3D

P6179

Q37361549-64D518EC-B920-490E-B26D-051485CFFCCC

P698

Q37361549-AD7DB4B0-C892-4719-880D-45794D915FE5

P921

Q37361549-71ABAA70-8573-42B6-BF1B-9DFF05A34158

P932

Q37361549-AD465AC3-E530-46A4-BE8A-5B9C1CEC82AA

P356

P1433

Experimental and Molecular Medicine

P1476

Phosphoproteomic analysis iden ...... ib-resistant cancer cell line.

@en

P2093

Byoung-Kyu Cho

http://www.w3.org/2001/XMLSchema#string

Eugene C Yi

http://www.w3.org/2001/XMLSchema#string

Hwang-Phill Kim

http://www.w3.org/2001/XMLSchema#string

Min Jueng Kang

http://www.w3.org/2001/XMLSchema#string

Sae-Won Han

http://www.w3.org/2001/XMLSchema#string

Tae-You Kim

http://www.w3.org/2001/XMLSchema#string

Yong Yook Lee

http://www.w3.org/2001/XMLSchema#string

P2860

A probability-based approach for high-throughput protein phosphorylation analysis and site localization

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

A statistical model for identifying proteins by tandem mass spectrometry

Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search

Lapatinib in the treatment of breast cancer

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.

Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens

Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system

P2888

P304

e64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EMM.2013.115

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258828734

http://www.w3.org/2001/XMLSchema#string

P6179

1025899051

http://www.w3.org/2001/XMLSchema#string

P698

24263233

http://www.w3.org/2001/XMLSchema#string

P921

P932

3849569

http://www.w3.org/2001/XMLSchema#string